...Corp. was in trouble. The New Jersey-based pharmaceutical and consumer products company, home of the allergy meds Nasonex and Claritin, was hemorrhaging market share in 2003, seeing its profits fall and facing costly manufacturing and compliance issues related...

... Paula Oertel (left) gets a helping hand from her sister, Terrie, last week in Oshkosh at Paula’s former apartment. Paula, who has an aggressive form of brain cancer, has moved into a nursing home as her condition worsened after Medicare denied approval of...

...STATION, N.J., March 19 /PRNewswire-FirstCall/ -- Schering-Plough Consumer HealthCare, a subsidiary of Merck & Co.(NYSE: MRK), and the maker of non-drowsy CLARITIN allergy medicines, wants to learn what millions of American allergy sufferers are able to do...

...In December it lost pharma account Boehringer ($200 million) to WPP's Mindshare without a review. Last month its Schering-Plough business went into play as a part of the Merck consolidation review, in which it is participating. MPG started off the new year...

...trial for the treatment of chemotherapy and post-operative-induced nausea and vomiting. The product was bought from Schering-Plough Corp. in October for $2 million in cash and up to $27 million in payments contingent upon meeting development milestones. Opko...

...in 1999. Merck said it is defending the patent and still believes it is valid and enforceable. Temodar was developed by Schering-Plough Corp. and the generic was developed by Barr Pharmaceuticals. Merck bought Schering-Plough in November, and Teva acquired...

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on

...In December it lost pharma account Boehringer ($200 million) to WPP's Mindshare without a review. Last month its Schering-Plough business went into play as a part of the Merck consolidation review, in which it is participating. MPG started off the new year...

...and has also worked at Johnson & Johnson, Astra-Merck, SmithKline and Rhone-Poulenc Rorer. Fred Hassan, who was CEO of Schering-Plough until its merger with Merck & Co, has been appointed chairman of the board at Bausch & Lomb. The company has also named...

... Today Simon Varcoe Please Login to read the full article. Former Schering-Plough CEO Fred Hassan has been appointed chairman of the eye-care specialists Bausch & Lomb. The appointment appears to have been planned well in advance...